News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
594,121 Results
Type
Article (47467)
Company Profile (299)
Press Release (546355)
Section
Business (168189)
Career Advice (1768)
Deals (28958)
Drug Delivery (123)
Drug Development (80182)
Employer Resources (131)
FDA (16165)
Job Trends (13087)
News (301546)
Policy (31834)
Tag
2024 BioCapital Digital (14)
2024 BioForest Digital (5)
2024 BioForest Standard (1)
2024 BioMidwest Digital (10)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (12)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (14)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (4)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (6)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (5)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Genetown Elite (1)
2026 Pharm Country Standard (1)
Academia (2426)
Academic (1)
Accelerated approval (3)
Adcomms (28)
Allergies (79)
Alliances (43648)
ALS (89)
Alzheimer's disease (1374)
Antibody-drug conjugate (ADC) (140)
Approvals (16138)
Artificial intelligence (254)
Autoimmune disease (21)
Automation (12)
Bankruptcy (256)
Best Places to Work (9982)
BIOSECURE Act (19)
Biosimilars (113)
Biotechnology (197)
Bladder cancer (61)
Brain cancer (28)
Breast cancer (254)
Cancer (1995)
Cardiovascular disease (174)
Career advice (1475)
Career pathing (29)
CAR-T (136)
Cell therapy (367)
Cervical cancer (19)
Clinical research (65223)
Collaboration (780)
Compensation (293)
Complete response letters (29)
COVID-19 (2450)
CRISPR (38)
C-suite (217)
Cystic fibrosis (94)
Data (1872)
Decentralized trials (2)
Denatured (29)
Depression (47)
Diabetes (257)
Diagnostics (4885)
Digital health (15)
Diversity (9)
Diversity, equity & inclusion (35)
Drug discovery (124)
Drug pricing (123)
Drug shortages (33)
Duchenne muscular dystrophy (85)
Earnings (61826)
Editorial (39)
Employer branding (14)
Employer resources (117)
Events (86557)
Executive appointments (655)
FDA (17311)
Featured Employer (46)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (662)
Gene editing (94)
Generative AI (24)
Gene therapy (291)
GLP-1 (786)
Government (4248)
Grass and pollen (3)
Guidances (46)
Healthcare (15815)
Huntington's disease (21)
IgA nephropathy (25)
Immunology and inflammation (118)
Indications (27)
Infectious disease (2580)
Inflammatory bowel disease (131)
Inflation Reduction Act (11)
Influenza (44)
Intellectual property (81)
Interviews (305)
IPO (12684)
IRA (51)
Job creations (3522)
Job search strategy (1259)
Kidney cancer (10)
Labor market (28)
Layoffs (478)
Leadership (17)
Legal (6793)
Liver cancer (67)
Lung cancer (294)
Lymphoma (136)
Machine learning (4)
Management (47)
Manufacturing (277)
MASH (63)
Medical device (9873)
Medtech (9878)
Mergers & acquisitions (16703)
Metabolic disorders (703)
Multiple sclerosis (74)
NASH (23)
Neurodegenerative disease (96)
Neuropsychiatric disorders (30)
Neuroscience (1882)
NextGen: Class of 2025 (5468)
Non-profit (3778)
Northern California (2121)
Now hiring (25)
Obesity (394)
Opinion (255)
Ovarian cancer (72)
Pain (82)
Pancreatic cancer (72)
Parkinson's disease (138)
Partnered (18)
Patents (192)
Patient recruitment (91)
Peanut (45)
People (53071)
Pharmaceutical (88)
Pharmacy benefit managers (21)
Phase I (19996)
Phase II (28285)
Phase III (21835)
Pipeline (1034)
Podcasts (97)
Policy (132)
Postmarket research (2910)
Preclinical (8309)
Press Release (68)
Prostate cancer (92)
Psychedelics (36)
Radiopharmaceuticals (236)
Rare diseases (362)
Real estate (4986)
Recruiting (52)
Regulatory (22818)
Reports (28)
Research institute (2255)
Resumes & cover letters (275)
Rett syndrome (3)
RNA editing (4)
RSV (41)
Schizophrenia (75)
Series A (121)
Series B (77)
Service/supplier (12)
Sickle cell disease (50)
Southern California (1835)
Special edition (18)
Spinal muscular atrophy (160)
Sponsored (27)
Startups (3275)
State (2)
Stomach cancer (14)
Supply chain (63)
The Weekly (66)
United States (18634)
Vaccines (657)
Venture capitalists (36)
Webinars (12)
Weight loss (288)
Women's health (26)
Worklife (14)
Date
Today (125)
Last 7 days (660)
Last 30 days (2591)
Last 365 days (30740)
2025 (7536)
2024 (32022)
2023 (35719)
2022 (46123)
2021 (49516)
2020 (47084)
2019 (40017)
2018 (30610)
2017 (29371)
2016 (28375)
2015 (32266)
2014 (25883)
2013 (21540)
2012 (23128)
2011 (23616)
2010 (21661)
Location
Africa (775)
Alabama (51)
Alaska (5)
Arizona (146)
Arkansas (13)
Asia (38428)
Australia (6375)
California (4831)
Canada (1703)
China (472)
Colorado (219)
Connecticut (238)
Delaware (118)
Europe (84569)
Florida (757)
Georgia (143)
Idaho (44)
Illinois (427)
India (25)
Indiana (256)
Iowa (7)
Japan (142)
Kansas (82)
Kentucky (24)
Louisiana (9)
Maine (37)
Maryland (770)
Massachusetts (3690)
Michigan (152)
Minnesota (280)
Mississippi (2)
Missouri (65)
Montana (28)
Nebraska (23)
Nevada (45)
New Hampshire (52)
New Jersey (1480)
New Mexico (31)
New York (1443)
North Carolina (852)
North Dakota (4)
Northern California (2121)
Ohio (159)
Oklahoma (14)
Oregon (35)
Pennsylvania (1055)
Puerto Rico (10)
Rhode Island (24)
South America (1035)
South Carolina (12)
South Dakota (1)
Southern California (1835)
Tennessee (75)
Texas (699)
Utah (124)
Virginia (139)
Washington D.C. (53)
Washington State (478)
West Virginia (2)
Wisconsin (50)
594,121 Results for "dr falk pharma gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States
Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, and European partner, Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), announce U.S Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for naronapride to treat patients with gastroparesis.
March 27, 2024
·
5 min read
Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories
Renexxion Ireland Limited announced that its European Partner, Dr. Falk Pharma GmbH, has elected to advance the development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease as the second indication in their licensed territories.
February 7, 2024
·
5 min read
Press Releases
Dr. Falk Pharma Acquires Kynos Therapeutics, Adding Acute Pancreatitis as a Therapeutic Focus and Further Strengthening Its Development Portfolio
October 29, 2024
·
4 min read
Press Releases
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Expansion of the Phase 2b MOVE-IT Study of Naronapride in Gastroparesis and Dosing of the First United States Patient
August 13, 2024
·
6 min read
Drug Development
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Ireland Limited, a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, is pleased to announce that the first patient has been treated in Europe with naronapride, a potential best-in-class pan-GI prokinetic, in a Phase IIb trial for gastroparesis conducted by Dr. Falk Pharma GmbH (Dr. Falk Pharma).
February 15, 2023
·
6 min read
Business
FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director
FundaMental Pharma GmbH announced the appointment of Dr. Lorenz Mayr to its Board of Directors.
March 20, 2024
·
3 min read
Business
FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer
FundaMental Pharma GmbH, a neuroscience company developing first-in-class small molecule inhibitors for the treatment of a range of neurodegenerative diseases, is pleased to announce the appointment of Dr. Dirk Beher as Chief Executive Officer and Executive Board member.
April 11, 2024
·
4 min read
Business
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy.
October 20, 2022
·
13 min read
Press Releases
Zymo Research Responds to Recent Court Ruling in Litigation with QIAGEN GmbH
March 19, 2025
·
1 min read
Government
Trump Threatens Big Pharma With Tariffs—Unless They Reshore Manufacturing: Bloomberg
President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.
February 24, 2025
·
2 min read
·
Tristan Manalac
1 of 59,413
Next